Adam Schechter

Adam Schechter has led Labcorp as CEO since 2019, overseeing one of the world's largest clinical laboratory companies. Labcorp operates more than 2,000 patient service centers and processes over 600,000 patient specimens daily, performing a vast range of diagnostic tests from routine blood work to complex genetic testing and specialty diagnostics. The company serves hospitals, physicians, pharmaceutical companies, and patients directly. Schechter navigated Labcorp through the COVID-19 pandemic, when the company became one of the largest COVID testing providers in the United States, dramatically scaling its testing capacity. Post-pandemic, he executed the spin-off of Labcorp's contract research organization (Fortrea) in 2023, refocusing the company on its core diagnostics business while retaining central laboratory and early development services that serve clinical trials. Labcorp's competitive position rests on its massive scale (enabling cost efficiency and geographic reach), broad test menu (offering thousands of different tests), and relationships with major health systems and insurance payers. Key stock drivers include diagnostic testing volumes, reimbursement rates from insurance companies, new test development (particularly in oncology and genomics), the post-COVID testing volume normalization, competition with Quest Diagnostics and hospital-based labs, and the growth of direct-to-consumer testing.